SCHEMBL5541440

SCHEMBL5541440

[CH2]CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.59
TGM2 P21980 1/20 0.59
KCNJ5 P48544 1/20 0.55
KCNJ3 P48549 1/20 0.55
KIF11 P52732 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 2/20 0.53
HTT P42858 1/20 0.53
ALDH1A1 P00352 1/20 0.52
POLB P06746 1/20 0.52
TRPV1 Q8NER1 2/20 0.51
PTGS1 P23219 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RHOC P08134 1/20 0.50
RHOA P61586 1/20 0.50
MTOR P42345 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142584 0.86 EPHX2 (0.70) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL5546267 0.86 EPHX2 (0.59) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL5544724 0.86 EPHX2 (0.46) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL2094723 0.83 EPHX2 (0.66) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL2094720 0.83 EPHX2 (0.66) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL9185912 0.83 EPHX2 (0.66) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL5541646 0.83 EPHX2 (0.56) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL5545780 0.82 EPHX2 (0.54) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL4008934 0.81 EPHX2 (0.63) EPHX2L3MBTL1TGM2KCNJ5KCNJ3
SCHEMBL31329595 0.81 EPHX2 (0.63) EPHX2L3MBTL1TGM2KCNJ5KCNJ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885L3MBTL1 1931/4885TGM2 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.